Signet Financial Management’s iShares Genomics Immunology and Healthcare ETF IDNA Stock Holding History
Bought
Maintained
Sold
Other funds holding IDNA
WBG
WAP
KAS
RJFSA
Signet Financial Management's IDNA Position: Q1 2022 in Review
Signet Financial Management sold out of iShares Genomics Immunology and Healthcare ETF (IDNA) in Q1 2022, closing a stake of 2,217 shares — an estimated $97K sold.
Signet Financial Management first reported a position in IDNA in Q4 2021 and held it in 1 quarter. The position peaked at $97K in Q4 2021. 86 funds tracked by Wall St. Rank hold IDNA as of Q1 2022.
- Signet Financial Management reported no remaining iShares Genomics Immunology and Healthcare ETF position as of Q1 2022 after selling out during the quarter.
- Signet Financial Management sold 2,217 iShares Genomics Immunology and Healthcare ETF shares in Q1 2022, an estimated $97K.
- Signet Financial Management first reported a position in iShares Genomics Immunology and Healthcare ETF in Q4 2021 and held it in 1 quarter.
- Signet Financial Management's iShares Genomics Immunology and Healthcare ETF position peaked at $97K in Q4 2021.
- 86 funds tracked by Wall St. Rank held iShares Genomics Immunology and Healthcare ETF as of Q1 2022.
Based on Signet Financial Management's 13F filing for Q1 2022, filed 13 May 2022.